1,862 reports of this reaction
1.3% of all INFLIXIMAB DYYB reports
#18 most reported adverse reaction
THERAPEUTIC RESPONSE SHORTENED is the #18 most commonly reported adverse reaction for INFLIXIMAB DYYB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 1,862 FDA adverse event reports linking INFLIXIMAB DYYB to THERAPEUTIC RESPONSE SHORTENED. This represents approximately 1.3% of all 142,758 adverse event reports for this drug.
Patients taking INFLIXIMAB DYYB who experience therapeutic response shortened should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC RESPONSE SHORTENED is a less commonly reported adverse event for INFLIXIMAB DYYB, but still significant enough to appear in the safety profile.
In addition to therapeutic response shortened, the following adverse reactions have been reported for INFLIXIMAB DYYB:
The following drugs have also been linked to therapeutic response shortened in FDA adverse event reports:
THERAPEUTIC RESPONSE SHORTENED has been reported as an adverse event in 1,862 FDA reports for INFLIXIMAB DYYB. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC RESPONSE SHORTENED accounts for approximately 1.3% of all adverse event reports for INFLIXIMAB DYYB, making it a notable side effect.
If you experience therapeutic response shortened while taking INFLIXIMAB DYYB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.